Hope For Autism Treatments – Journal of Immunology – GcMAF therapy helps Improve Children with Autism

GcMAF-Quote-Autism-TherapyGc-MAF (or Gc protein-derived macrophage activating factor) is an immunomodulatory protein that, by affecting the immune system, may play a role in various diseases.

We are heavily investigating and researching this treatment and found more than 120+ studies from scientists and doctors on GcMAF.

All of the clinic studies are public information, yet no one is talking about it…why…because it’s blocked from being used in America. People who speak about GcMAF are labeled “quacks”, but the science and studies behind this treatment show tremendous success in the treatment of children with Autism.

We are seeking a brave hospital in North America to answer the calling of the world, there is too much hope in biomedical interventions for people seeking to improve the quality of life for their child.  We all seek this…we will find them!

The text below is from a clinic in Japan who has successfully treated nearly 2,000 patients with Autism and other disorders successfully with a 45% effectiveness rate overall…

Conventional management of Autism

More than half of US children diagnosed with ASD are prescribed psychoactive drugs or anticonvulsants, with the most common drug classes being antidepressants, stimulants, and antipsychotics. Aside from antipsychotics, there is scant reliable research about the effectiveness or safety of drug treatments for adolescents and adults with ASD. A person with autism may respond atypically to medications, the medications can have adverse effects, and no known medication relieves autism’s core symptoms of social and communication impairments.

So essentially, conventional management of Autism does not address the cause of the disease and only attempts to treat the symptoms.

 

The immune system and Autism

Recently it is becoming clear that immune system disfunction plays an important role in autism.

Altered immunity in individuals with Autism

Immunological abnormalities involving cytokines, immunoglobulins, inflammation and cellular activation have been noted in individuals with autism.

Alterations in various immune cells including Natural Killer Cells and Macrophages have also been observed in individuals with autism. Upon stimulation, NK cells from individuals with autism showed diminished cytotoxic activity.

Macrophage migration inhibitory factor (MIF or MMIF)

A cytokine recently linked to autism is macrophage migration inhibitory factor (MIF). MIF is a pro-inflammatory immune regulator that is constitutively expressed in brain tissues, and has important influences on neural and endocrine systems. This macrophage migration inhibitory factor cytokine is produced by neuroendocrine and immune tissues. Macrophage migration inhibitory factor possesses glucocorticoid-antagonist properties within the immune system and participates in the regulation of several endocrine circuits.

  • Plasma levels of macrophage migration inhibitory factor (MIF) were higher in individuals with autism.
  • Individuals with autism with the highest levels of plasma MIF were found to have the most severe behavioral symptoms.
  • Macrophage migration inhibitory factor is of critical importance for the host response to microbial infections and in several autoimmune diseases.
  • Macrophage migration inhibitory factor expression is usually constitutive at low levels.

Immunoglobulin Levels

  • Decreased levels of total plasma IgG and IgM have been observed in a large group of individuals with autism.
  • The reduced levels correlated with behavior, such that individuals with autism with the most severe behavioral symptom scores had the lowest IgG and IgM levels.

Altered sensitivity to environmental toxicants – PBDEs, immunity and autism

A complex interplay between immunological and environmental factors may have a role in autism. Polybrominated diphenyl ethers (PBDEs) are environmental toxicants that impact neurodevelopment and immunity. Individuals with ASD have different immune sensitivity to the environmental toxicant

 

GcMAF therapy for the treatment of Autism

High Dose GcMAF immunotherapy is administered to overcome the problem of immune system disfunction, including that of macrophage migration inhibitory factor (MIF), which plays an integral role in autism and leads to commonly observed symptoms.

– read more at: http://BrainStudies.org

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s